Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...

Brad Sigmon will be put to death March 7 It will be the first time a firing squad is used in 15 years Some say a firing squad may be more humane than lethal injections Sigmon chose a firing squad over ...

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug ...

Chelsea Blackwell is chasing her revenge body.After receiving floods of hate following the Netflix show's finale, Blackwell ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration (FDA) to look into foreign-made active pharmaceutical ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

The issuer is solely responsible for the content of this announcement.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.